VITURA HEALTH LIMITED (VIT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

VIT - VITURA HEALTH LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 1.69
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.08

23 Dec
2024

0.000

OPEN

$0.08

0.000

HIGH

$0.08

37,512

LOW

$0.08

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

Last ex-div: 04/09 - ex-div 1c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx0.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx123.9 M
Book Value Per Share xxxxxxxxxxxxxxx6.7
Net Operating Cash Flow xxxxxxxxxxxxxxx7.0 M
Net Profit Margin xxxxxxxxxxxxxxx2.84 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx9.52 %
Return on Invested Capital xxxxxxxxxxxxxxx8.35 %
Return on Assets xxxxxxxxxxxxxxx5.94 %
Return on Equity xxxxxxxxxxxxxxx9.52 %
Return on Total Capital xxxxxxxxxxxxxxx11.37 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx1.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx9 M
Total Debt xxxxxxxxxxxxxxx11 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx11 M
Price To Book Value xxxxxxxxxxxxxxx1.28

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.8 M
Capex % of Sales xxxxxxxxxxxxxxx0.63 %
Cost of Goods Sold xxxxxxxxxxxxxxx111 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx8 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Petra Capital

11/09/2024

1

Speculative Buy

$0.12

50.00%

Petra Capital responded to the Vitura Health trading update with a dose of scepticism, highlighting the analyst would like to see tangible evidence of a turnaround before changing earnings forecasts.

In the first two months of FY25, the business is trading ahead of budget with 10% revenue growth and an increase in the EBITDA margin.

The broker is seeking price stabilisation and more durable price improvements post what has been a very competitive medicinal cannabis distribution environment.

The Speculative Buy rating and 12c target are unchanged.

FORECAST
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of 1.00 cents.
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.40 cents.
Access Extra Coverage Research History >

VIT STOCK CHART

FNArena News on VIT

1
Australian Broker Call *Extra* Edition – Sep 11, 2024

Sep 11 2024 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Sep 09, 2024

Sep 09 2024 - Daily Market Reports
3
In Case You Missed It – BC Extra Upgrades & Downgrades – 06-09-24

Sep 06 2024 - Weekly Reports
4
Australian Broker Call *Extra* Edition – Sep 05, 2024

Sep 05 2024 - Daily Market Reports
5
In Case You Missed It – BC Extra Upgrades & Downgrades – 07-06-24

Jun 07 2024 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps